Mildly elevated liver lipid content is characterised by reduced insulin sensitivity

dc.contributor.authorTuomola, Nelli
dc.contributor.authorRebelos, Eleni
dc.contributor.authorLatva-Rasku, Aino
dc.contributor.authorBucci, Marco
dc.contributor.authorImmonen, Heidi
dc.contributor.authorSaunavaara, Virva
dc.contributor.authorLaine, Saara
dc.contributor.authorSjöros, Tanja
dc.contributor.authorGarthwaite, Taru
dc.contributor.authorRaiko, Juho R.H.
dc.contributor.authorFernandes Silva, Lilian
dc.contributor.authorVirtanen, Kirsi A.
dc.contributor.authorHannukainen, Jarna C.
dc.contributor.authorAla-Korpela, Mika
dc.contributor.authorKalliokoski, Kari K.
dc.contributor.authorHeinonen, Ilkka H.A.
dc.contributor.authorNuutila, Pirjo
dc.contributor.authorHonka, Miikka-Juhani
dc.contributor.organizationfi=PET-keskus|en=Turku PET Centre|
dc.contributor.organizationfi=kliininen laitos|en=Department of Clinical Medicine|
dc.contributor.organizationfi=sisätautioppi|en=Internal Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.14646305228
dc.contributor.organization-code1.2.246.10.2458963.20.40502528769
dc.contributor.organization-code1.2.246.10.2458963.20.61334543354
dc.contributor.organization-code2609810
dc.converis.publication-id504757116
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/504757116
dc.date.accessioned2026-01-21T13:38:01Z
dc.date.available2026-01-21T13:38:01Z
dc.description.abstract<h3>Background & Aims</h3><p>Recently, a new cut-off of ≤1.85% was proposed for normal liver lipid content based on a large population trial. In that study, people having liver lipid between 1.86% and the currently used magnetic resonance spectroscopy-specific upper limit of 5.56% had lower insulin sensitivity (higher homeostatic model assessment for insulin resistance [HOMA-IR]) when compared with people with ≤1.85% of liver lipid. We aimed to build upon these findings by evaluating differences in tissue-specific insulin sensitivity between individuals having low (LL; ≤1.85%) or mildly elevated (MEL; >1.85% and ≤5.56%) liver lipids.</p><h3>Methods</h3><p>Combining data from previous studies, 202 White European individuals without diabetes were included in this cross-sectional study. Liver lipids were measured with magnetic resonance spectroscopy. Endogenous glucose production (EGP; N = 96) was measured by hyperinsulinaemic–euglycaemic clamp combined with [<sup>18</sup>F]fluorodeoxyglucose positron emission tomography, and adipose tissue insulin resistance by the product of fasting free fatty acids and insulin (N = 197). Serum metabolites were measured using nuclear magnetic resonance metabolomics (N = 152).</p><h3>Results</h3><p>The MEL group had higher EGP during hyperinsulinemia (2.7 [-0.4; 7.5] <em>vs.</em> -0.2 [-4.3; 5.3] μmol/kg/min, <em>p</em> = 0.041) and higher adipose tissue insulin resistance at fasting (28.4 [16.6; 37.5] <em>vs.</em> 17.6 [9.6; 26.9] pmol/L × mmol/L, <em>p</em> = 0.037) compared with the LL group. In addition, serum triglycerides and branched-chain amino acids were elevated (false discovery rate <0.05) compared with the LL group.</p><h3>Conclusions</h3><p>People with MEL had lower hepatic and adipose tissue insulin sensitivity and adverse changes in metabolites when compared with people with LL. These findings support a lower upper limit for normal liver lipids in White Europeans. In addition, the data indicate that impaired suppression of EGP during hyperinsulinaemia and insulin resistance of lipolysis are early features in the cascade of systemic insulin resistance.</p><h3>Impact and implications</h3><p>It has long been known that a substantially increased liver lipid content is connected to an increase in cardiovascular risk factors. From the perspective of both researchers and clinicians, it is important to know that even slightly elevated liver lipid content is associated with many adverse metabolic changes. Further research is needed to confirm if intervening early in the development of fatty liver with lifestyle intervention and, if necessary, drug treatment at an early stage, provide benefit for the prevention of metabolic diseases in the future.</p>
dc.identifier.eissn2589-5559
dc.identifier.olddbid213197
dc.identifier.oldhandle10024/196215
dc.identifier.urihttps://www.utupub.fi/handle/11111/54910
dc.identifier.urlhttps://doi.org/10.1016/j.jhepr.2025.101535
dc.identifier.urnURN:NBN:fi-fe202601217354
dc.language.isoen
dc.okm.affiliatedauthorTuomola, Nelli
dc.okm.affiliatedauthorRebelos, Eleni
dc.okm.affiliatedauthorLatva-Rasku, Aino
dc.okm.affiliatedauthorBucci, Marco
dc.okm.affiliatedauthorImmonen, Heidi
dc.okm.affiliatedauthorSaunavaara, Virva
dc.okm.affiliatedauthorLaine, Saara
dc.okm.affiliatedauthorSjöros, Tanja
dc.okm.affiliatedauthorGarthwaite, Taru
dc.okm.affiliatedauthorRaiko, Juho
dc.okm.affiliatedauthorVirtanen, Kirsi
dc.okm.affiliatedauthorHannukainen, Jarna
dc.okm.affiliatedauthorKalliokoski, Kari
dc.okm.affiliatedauthorHeinonen, Ilkka
dc.okm.affiliatedauthorNuutila, Pirjo
dc.okm.affiliatedauthorHonka, Miikka
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherElsevier
dc.publisher.countryNetherlandsen_GB
dc.publisher.countryAlankomaatfi_FI
dc.publisher.country-codeNL
dc.relation.articlenumber101535
dc.relation.doi10.1016/j.jhepr.2025.101535
dc.relation.ispartofjournalJHEP Reports
dc.relation.issue11
dc.relation.volume7
dc.source.identifierhttps://www.utupub.fi/handle/10024/196215
dc.titleMildly elevated liver lipid content is characterised by reduced insulin sensitivity
dc.year.issued2025

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
1-s2.0-S2589555925002149-main.pdf
Size:
1.24 MB
Format:
Adobe Portable Document Format